Cover Image

In silico docking and pharmacophoric analysis of 3-indolyl pyridine derivatives toward cyclooxygenase-2

Sukumar Bepary, Ge Hyeong Lee, Hee Jong Lim, In Kwon Youn

Abstract


Good Pharmacy Practice (GPP) in community and hospital pharmacy setting is a crucial standard for pharmacy services. The Thai Food and Drug Administration (Thai-FDA) realized the benefit of GPP and tried to implement this concept as a regulation for every community pharmacy. As a result, the Ministerial Regulation on Application and Issuance of License to Modern Pharmacies was implemented, so the new community pharmacies which open after the issue of this regulation must abide by it if they open after 26th June 2014. However, the Thai-FDA gave a period within eight years for old pharmacies to adapt to this new regulation.  Thus, this study aimed to explore the economic impact in terms of cost-benefit of the Ministerial Regulation on Application and Issuance of License to Modern Pharmacies. This regulation was revised to improve the quality and standard of community pharmacies. The data was obtained from self-administered questionnaires sent to Type I pharmacy owners, excluding the accredited pharmacies, and from the published literature and expert opinion. This study was performed from a societal perspective. The result showed that the total 8-year cost was $1,317.90 million dollars (48,639.61 million baht) and total 8-year benefit was $3,672.34 million dollars (136,027.69 million baht). NPV and benefit to cost ratio were $ 2,087.79 million dollars (68,458.75 million baht) and 2.79 benefit: cost, respectively. The one-way best case and worse case sensitivity result presented that the net benefit ranged from -$856.14 million dollars to $20,815.45 million dollars (– 28,072.91 to 682,538.71 million baht). Cost of pharmacy closing down was the least sensitive variable in this model. Cost of Drug-Related problem (DRP) per case and number of DRPs in community pharmacies were the important factors which might contribute to an impact on net benefit. The implementation of this regulation seems to have provided positive financial return on investment to Thai society.

Full Text:

35-40:PDF

References


S. M. Paul, D. S. Mytelka, C. T. Dunwiddie, C. C. Persinger, B. H. Munos, S. R. Lindborg and A. L. Schacht. How to improve R&D productivity: the pharmaceutical industry’s grand challenge, Nat Rev Drug Discoy. 9(3): 203–214 (2010).

P. Cuatrecasas. Drug discovery in jeopardy, J Clin Invest. 116(11): 2837-2842 (2006).

I. Kola and J. Landis. Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov. 3(8): 711–715 (2004).

D. B. Kitchen et al. Docking and scoring in virtual screening for drug discovery: methods and applications, Nat Rev Drug Discov. 3(11): 935– 949 (2004).

I. Halperin et al. Principles of docking: an overview of search algorithms and a guide to scoring functions, Proteins. 47(4): 409–443 (2002).

G. L. Warren et al. A critical assessment of docking programs and scoring functions, J Med Chem. 49(20): 5912–5931 (2006).

M. Jacobsson et al. Improving structure-based virtual screening by multivariate analysis of scoring data, J Med Chem. 46(26): 5781–5789 (2003).

K. Loving, N. K. Salam and W. Sherman. Energetic analysis of fragment docking and application to structure-based pharmacophore hypothesis generation, J Comput Aided Mol Des. 23(8): 541–554 (2009). [9] D. Wei et al. Binding energy landscape analysis helps to discriminate true hits from high-scoring decoys in virtual screening, J Chem Inf Model. 50(10): 1855–1864 (2010).

M. I. Zavodszky et al. Scoring ligand similarity in structure-based virtual screening, J Mol Recognit. 22(4): 280–292 (2009).

P. Ripphausen et al. Quo vadis, virtual screening? A comprehensive survey of prospective applications, J Med Chem. 53(24): 8461–8467 (2010).

S. F. Sousa et al. Virtual screening in drug design and development, Comb Chem High Throughput Screen. 13(5): 442–453 (2010).

K. Seibert, Y. Zhang, K. Leahy, et al. Pharmacological and biochemical demonstration of the role of cyclooxygenase 2 in inflammation and pain, Proc Natl Acad Sci USA. 91: 12013-7 (1994). [14] L. J. Crofford, R. L. Wilder, A. P. Ristimaki et al. Cyclooxygenase- 1 and 2 expression in rheumatoid synovial tissues. Effects of interleukin- 1ß, phorbol ester, and corticosteroids. J Clin Invest. 93: 1095-101 (1994).

F. Nantel, D. Denis, R. Gordon et al. Distribution and regulation of cyclooxygenase-2 in carrageenan-induced inflammation. Br J Pharmacol.128: 853-9 (1999).

J. L. Masferrer, B. S. Zweifel, P. T. Manning et al. Selective inhibition of inducible cyclooxygenase-2 in vivo is antiinflammatory and nonulcerogenic. Proc Natl Acad Sci USA. 91: 3228-32 (1994).

G. D. Anderson, S. D. Hauser, K. L. McGarity, M. E. Bremer, P. C. Isakson, S. A. Gregory. Selective inhibition of cyclooxygenase (COX)-2 reverses inflammation and expression of COX-2 and interleukin 6 in rat adjuvant arthritis. J Clin Invest. 97: 2672-9 (1996).

J. A. Mitchell, P. Akarasereenont, C. Thiemermann, R. J. Flower, J. R. Vane. Selectivity of nonsteroidal antiinflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase. Proc Natl Acad Sci USA. 90: 11693-7 (1994).

T. D. Warner, F. Giuliano, I. Vojnovic, A. Bukasa, J. A. Mitchell, J. R. Vane. Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis. Proc Natl Acad Sci USA.96: 7563-8 (1999).

P. Thirumurugan, S. Mahalaxmi and P. T. Perumal. Synthesis and anti-inflammatory activity of 3-indolyl pyridine derivatives through one- pot multi component reaction, J. Chem. Sci. 122(6): 819–832 (2010). [21] O. Trott et al. AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading, J Comput Chem. 31(2): 455-461 (2010).


Refbacks

  • There are currently no refbacks.